anti-galectin-9 monoclonal antibody lyt-200
Generic: Anti-galectin-9 Monoclonal Antibody LYT-200
anti-galectin-9 monoclonal antibody lyt-200: 1 clinical trial tracked.
anti-galectin-9 monoclonal antibody lyt-200 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-galectin-9 monoclonal antibody lyt-200, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and RP2D determination]
Interventionalopen101 enrolledStarted 2022-12Completion 2025-129 sites · United StatesPureTech